HELLS and prostate cancer: Our findings that HELLS-deficient HAP1 cells exhibit increased sensitivity to PARP inhibition (Fig. 3A–C) are consistent with several CRISPR screen-based studies identifying HELLS as a mediator of PARPi sensitivity in breast, ovarian, and prostate cancer [66–68].